Marc Davies

Vice President of R&D • Leucid Bio

Marc Davies received his PhD from the laboratory of Dr John Maher at King’s College London, where his research focussed on the development and pre-clinical assessment of CAR T-cells targeting the extended ErbB family. This product is now under investigation in an investigator-led Phase I clinical trial for patients with relapsed/refractory head and neck cancer. Following a post-doctoral position at University College London developing CAR T-cells for haematological malignancies, Marc returned to KCL where his research focussed on enhancing CAR T-cell efficacy against solid tumours. With over 15 years of experience in the field of adoptive cell therapy, Marc joined Leucid Bio in May 2021 as VP of CAR Engineering to manage their burgeoning CAR T-cell R&D pipeline and clinical translation of their lead asset, LEU011.

Also speaking

Ingrid Gafanhão

Equity Research Analyst, Healthcare • Bryan, Garnier & Co.

Michal Besser

Chief Technology Officer, Davidoff Cancer Center • Rabin Medical Center

Emmanuelle Cameau

Strategic Technology Partnership Leader • Cytiva

Event Info


Sponsorship Opportunities Waiting List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.


Find out more about partnering at Advanced Therapies Europe.